GlassScriptPhysician profile
Toni Nicole Wright
NPI 1598227175
$3,574.76
in general payments reported to CMS, 2019-2025
29 companies · $2,077 in 2025
The $2,077 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $146 · 2024: $1,352 · 2025: $2,077.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,526 · Education: $48.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,525.92 |
| Education | $48.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $660.79 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $514.64 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Amgen INC. | $494.01 | 2023-2025 | Repatha, Otezla, Repatha |
| Glaxosmithkline, LLC. | $247.05 | 2024-2025 | Trelegy Ellipta, Arexvy |
| Novo Nordisk INC | $232.35 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $216.39 | 2023-2024 | Caplyta |
| Vanda Pharmaceuticals INC. | $212.35 | 2025 | Fanapt |
| Teva Pharmaceuticals USA, INC. | $174.13 | 2024-2025 | Austedo Xr, Ajovy, Austedo Xr |
| Lilly USA, LLC | $116.43 | 2023-2025 | Zepbound, Mounjaro, Jardiance |
| Phathom Pharmaceuticals, INC. | $82.98 | 2024-2025 | Voquezna |
| Pfizer INC. | $78.66 | 2024-2025 | |
| Alkermes, INC. | $72.57 | 2025 | Lybalvi, Vivitrol |
| Almatica Pharma LLC | $55.64 | 2024-2025 | Loreev Xr |
| Abbott Laboratories | $55.15 | 2023-2025 | Freestyle Libre 3, Freestyle Libre |
| Insulet Corporation | $52.66 | 2025 | Omnipod |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verona Pharma, INC. | $50.22 | 2025 | Ohtuvayre |
| Azurity Pharmaceuticals, INC. | $34.30 | 2024 | Edarbi |
| Corcept Therapeutics | $30.78 | 2024 | Korlym |
| Bayer Healthcare Pharmaceuticals INC. | $23.35 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.18 | 2024 | Xifaxan, Trulance |
| Tolmar, INC. | $18.02 | 2025 | Jatenzo |
| Takeda Pharmaceuticals U.S.A., INC. | $17.78 | 2023 | Trintellix |
| Novartis Pharmaceuticals Corporation | $17.45 | 2025 | |
| Idorsia Pharmaceuticals US INC | $17.44 | 2025 | Quviviq |
| Exact Sciences Corporation | $17.27 | 2025 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $16.96 | 2025 | |
| Astellas Pharma US INC | $16.73 | 2024 | Veozah |
| Axsome Therapeutics, INC. | $16.25 | 2024 | Auvelity |
| Mylan Specialty L.P. | $13.23 | 2024 | Yupelri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Toni Wright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.